Study of RH-1 in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Status:
Terminated
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1, nonrandomized, open-label, dose-escalation study of 3-hour IV infusions of
RH-1 administered to patients with advanced solid tumors or non-Hodgkin's lymphoma (NHL).
Treatment will continue until a patient meets criteria for discontinuation.